BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 36499245)

  • 21. Epithelial-to-mesenchymal transition mediates docetaxel resistance and high risk of relapse in prostate cancer.
    Marín-Aguilera M; Codony-Servat J; Reig Ò; Lozano JJ; Fernández PL; Pereira MV; Jiménez N; Donovan M; Puig P; Mengual L; Bermudo R; Font A; Gallardo E; Ribal MJ; Alcaraz A; Gascón P; Mellado B
    Mol Cancer Ther; 2014 May; 13(5):1270-84. PubMed ID: 24659820
    [TBL] [Abstract][Full Text] [Related]  

  • 22. TMPRSS4 promotes cancer stem-like properties in prostate cancer cells through upregulation of SOX2 by SLUG and TWIST1.
    Lee Y; Yoon J; Ko D; Yu M; Lee S; Kim S
    J Exp Clin Cancer Res; 2021 Nov; 40(1):372. PubMed ID: 34809669
    [TBL] [Abstract][Full Text] [Related]  

  • 23. miR-199b-5p-DDR1-ERK signalling axis suppresses prostate cancer metastasis via inhibiting epithelial-mesenchymal transition.
    Zhao Z; Zhao S; Luo L; Xiang Q; Zhu Z; Wang J; Liu Y; Luo J
    Br J Cancer; 2021 Mar; 124(5):982-994. PubMed ID: 33239676
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The involvement of FBP1 in prostate cancer cell epithelial mesenchymal transition, invasion and metastasis by regulating the MAPK signaling pathway.
    Zhang YP; Liu KL; Yang Z; Lu BS; Qi JC; Han ZW; Yin YW; Zhang M; Chen DM; Wang XW; Li W; Xin H
    Cell Cycle; 2019 Oct; 18(19):2432-2446. PubMed ID: 31448674
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Non-Coding RNAs Set a New Phenotypic Frontier in Prostate Cancer Metastasis and Resistance.
    Altschuler J; Stockert JA; Kyprianou N
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33672595
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long noncoding RNA LINC00963 induces NOP2 expression by sponging tumor suppressor miR-542-3p to promote metastasis in prostate cancer.
    Sun F; Wu K; Yao Z; Mu X; Zheng Z; Sun M; Wang Y; Liu Z; Zhu Y
    Aging (Albany NY); 2020 Jun; 12(12):11500-11516. PubMed ID: 32554858
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Wild-type p53 suppresses the epithelial-mesenchymal transition and stemness in PC-3 prostate cancer cells by modulating miR‑145.
    Ren D; Wang M; Guo W; Zhao X; Tu X; Huang S; Zou X; Peng X
    Int J Oncol; 2013 Apr; 42(4):1473-81. PubMed ID: 23404342
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A switch from CD44⁺ cell to EMT cell drives the metastasis of prostate cancer.
    Shang Z; Cai Q; Zhang M; Zhu S; Ma Y; Sun L; Jiang N; Tian J; Niu X; Chen J; Sun Y; Niu Y
    Oncotarget; 2015 Jan; 6(2):1202-16. PubMed ID: 25483103
    [TBL] [Abstract][Full Text] [Related]  

  • 29. DNMT1 Regulates Epithelial-Mesenchymal Transition and Cancer Stem Cells, Which Promotes Prostate Cancer Metastasis.
    Lee E; Wang J; Yumoto K; Jung Y; Cackowski FC; Decker AM; Li Y; Franceschi RT; Pienta KJ; Taichman RS
    Neoplasia; 2016 Sep; 18(9):553-66. PubMed ID: 27659015
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epithelial-mesenchymal transition in prostate cancer: an overview.
    Montanari M; Rossetti S; Cavaliere C; D'Aniello C; Malzone MG; Vanacore D; Di Franco R; La Mantia E; Iovane G; Piscitelli R; Muscariello R; Berretta M; Perdonà S; Muto P; Botti G; Bianchi AAM; Veneziani BM; Facchini G
    Oncotarget; 2017 May; 8(21):35376-35389. PubMed ID: 28430640
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Estrogen receptor α-NOTCH1 axis enhances basal stem-like cells and epithelial-mesenchymal transition phenotypes in prostate cancer.
    Shen Y; Cao J; Liang Z; Lin Q; Wang J; Yang X; Zhang R; Zong J; Du X; Peng Y; Zhang J; Shi J
    Cell Commun Signal; 2019 May; 17(1):50. PubMed ID: 31122254
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SMC1A is associated with radioresistance in prostate cancer and acts by regulating epithelial-mesenchymal transition and cancer stem-like properties.
    Yadav S; Kowolik CM; Lin M; Zuro D; Hui SK; Riggs AD; Horne DA
    Mol Carcinog; 2019 Jan; 58(1):113-125. PubMed ID: 30242889
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Double-negative feedback loop between ZEB2 and miR-145 regulates epithelial-mesenchymal transition and stem cell properties in prostate cancer cells.
    Ren D; Wang M; Guo W; Huang S; Wang Z; Zhao X; Du H; Song L; Peng X
    Cell Tissue Res; 2014 Dec; 358(3):763-78. PubMed ID: 25296715
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MUC15 loss facilitates epithelial-mesenchymal transition and cancer stemness for prostate cancer metastasis through GSK3β/β-catenin signaling.
    Wu S; Yue Y; Gu Y; Wang Q; Liu T; Li L; Wang X; Chang LS; He D; Wu K
    Cell Signal; 2021 Aug; 84():110015. PubMed ID: 33894313
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epithelial-to-mesenchymal transition leads to disease-stage differences in circulating tumor cell detection and metastasis in pre-clinical models of prostate cancer.
    Lowes LE; Goodale D; Xia Y; Postenka C; Piaseczny MM; Paczkowski F; Allan AL
    Oncotarget; 2016 Nov; 7(46):76125-76139. PubMed ID: 27764810
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Androgen receptor splice variants contribute to prostate cancer aggressiveness through induction of EMT and expression of stem cell marker genes.
    Kong D; Sethi S; Li Y; Chen W; Sakr WA; Heath E; Sarkar FH
    Prostate; 2015 Feb; 75(2):161-74. PubMed ID: 25307492
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mesenchymal stem cells recruited by castration-induced inflammation activation accelerate prostate cancer hormone resistance via chemokine ligand 5 secretion.
    Yu Y; Zhang Q; Ma C; Yang X; Lin R; Zhang H; Liu Y; Han Z; Cheng J
    Stem Cell Res Ther; 2018 Sep; 9(1):242. PubMed ID: 30257726
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MiR-573 inhibits prostate cancer metastasis by regulating epithelial-mesenchymal transition.
    Wang L; Song G; Tan W; Qi M; Zhang L; Chan J; Yu J; Han J; Han B
    Oncotarget; 2015 Nov; 6(34):35978-90. PubMed ID: 26451614
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Loss of exosomal miR-146a-5p from cancer-associated fibroblasts after androgen deprivation therapy contributes to prostate cancer metastasis.
    Zhang Y; Zhao J; Ding M; Su Y; Cui D; Jiang C; Zhao S; Jia G; Wang X; Ruan Y; Jing Y; Xia S; Han B
    J Exp Clin Cancer Res; 2020 Dec; 39(1):282. PubMed ID: 33317606
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Emerging therapeutics targeting castration-resistant prostate cancer: the AR-mageddon of tumor epithelial-mesenchymal transition.
    Hendrix LN; Hamilton DA; Kyprianou N
    Expert Rev Endocrinol Metab; 2013 Jul; 8(4):403-416. PubMed ID: 30736155
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.